Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gram-negative Infection Clear all
Recruiting Not applicable Interventional

Modernizing Perinatal Syphilis Testing

NCT06082453
View directory record Official record
Conditions
Syphilis
Interventions
Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum, Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum, Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis
Diagnostic Test · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 45 Years
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jul 21, 2026, 12:16 PM EDT
Completed No phase listed Observational

Gram Negative Bacteremia, Risk Factors for Failure of Therapy

NCT00177957
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Jul 21, 2026, 12:16 PM EDT
Completed No phase listed Observational

Community-associated Highly-Resistant Enterobacterales

NCT03924934
View directory record Official record
Conditions
Enterobacteriaceae Infections, Community-Acquired Infections, Healthcare Associated Infection, Carbapenem-Resistant Enterobacteriaceae Infection
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
2,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Different Pediatric Combination Vaccines.

NCT00255047
View directory record Official record
Conditions
Diphtheria, Polio, Pertussis
Interventions
DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
36
States / cities
Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2008 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Not applicable Interventional

Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

NCT00002052
View directory record Official record
Conditions
HIV Infections, Salmonella Infections
Interventions
Ceftriaxone sodium, Ampicillin sodium, Amoxicillin trihydrate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

NCT01585181
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Lexington, Kentucky • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake

NCT04678271
View directory record Official record
Conditions
Influenza, Whooping Cough
Interventions
AFIX-OB Quality Improvement Package
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

NCT02531685
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Not applicable Interventional

Self Sampling for Rapid Turnaround Testing in the Emergency Department

NCT03676816
View directory record Official record
Conditions
Chlamydia Trachomatis, Neisseria Gonorrhoeae
Interventions
vaginal self sampling, provider-performed endocervical sampling
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01595438
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sylmar, California • Royal Oak, Michigan • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

NCT00359983
View directory record Official record
Conditions
Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions
MenHibrix (Hib-MenCY-TT), Hib conjugate vaccine (ActHIB)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
22 Months to 60 Months
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
21
States / cities
Little Rock, Arkansas • Fountain Valley, California • Norwich, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jul 21, 2026, 12:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

NCT01129362
View directory record Official record
Conditions
Pertussis
Interventions
Pentacel® (DTaP-IPV/Hib), Other Pertussis Vaccines
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Up to 59 Months
Enrollment
1,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Not applicable Interventional

A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic Patients

NCT02862262
View directory record Official record
Conditions
Bordetella Infections, Bordetella Pertussis Infection, Bordetella Parapertussis Infection
Interventions
ARIES Bordetella Assay
Device
Lead sponsor
Luminex Molecular Diagnostics
Industry
Eligibility
Not listed
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
5
States / cities
Indianapolis, Indiana • Grosse Pointe Woods, Michigan • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Jul 21, 2026, 12:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru

NCT00023582
View directory record Official record
Conditions
HIV Infections, Herpes Genitalis, HIV Seronegativity, Syphilis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Jul 21, 2026, 12:16 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Azithromycin in Control of Trachoma II

NCT00286026
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Jul 21, 2026, 12:16 PM EDT
Completed No phase listed Observational

Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol

NCT00877708
View directory record Official record
Conditions
E Coli Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jul 21, 2026, 12:16 PM EDT
Completed No phase listed Observational

Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli

NCT00573235
View directory record Official record
Conditions
Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

NCT05477524
View directory record Official record
Conditions
Lyme Disease
Interventions
VLA15, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
5 Years and older
Enrollment
12,546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
82
States / cities
Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®

NCT00319553
View directory record Official record
Conditions
Pertussis, Tetanus, Diphtheria
Interventions
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
11 Years to 18 Years
Enrollment
647 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
10
States / cities
Annapolis, Maryland • Baltimore, Maryland • Frederick, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Jul 21, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Online HIV Prevention for Young Male Couples

NCT03284541
View directory record Official record
Conditions
Hiv, Chlamydia, Gonorrhea
Interventions
2GETHER, Existing Public Health Practice
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jul 21, 2026, 12:16 PM EDT
Completed No phase listed Observational

Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia

NCT01140022
View directory record Official record
Conditions
Chlamydia, Screening
Interventions
CT Screening
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fresno, California • Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Jul 21, 2026, 12:16 PM EDT